IONS Stock Forecast 2025-2026
Distance to IONS Price Targets
IONS Price Momentum
10 Quality Stocks Worth Considering Now
Researching Ionis (IONS) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on IONS and similar high-potential opportunities.
Latest IONS Stock Price Targets & Analyst Predictions
Based on our analysis of 32 Wall Street analysts, IONS has a bullish consensus with a median price target of $59.50 (ranging from $37.00 to $78.00). The overall analyst rating is Strong Buy (8.2/10). Currently trading at $28.40, the median forecast implies a 109.5% upside. This outlook is supported by 17 Buy, 8 Hold, and 1 Sell ratings.
Conversely, the most conservative target is provided by Salveen Richter at Goldman Sachs, suggesting a 30.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IONS Analyst Ratings
IONS Price Target Range
Latest IONS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IONS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 15, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $60.00 |
| Apr 8, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $60.00 |
| Apr 7, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Initiates | $45.00 |
| Apr 3, 2025 | Guggenheim | Debjit Chattopadhyay | Buy | Reiterates | $0.00 |
| Mar 31, 2025 | Redburn Atlantic | Joshua Smith | Neutral | Initiates | $39.00 |
| Mar 24, 2025 | JP Morgan | Jessica Fye | Neutral | Maintains | $45.00 |
| Mar 11, 2025 | JP Morgan | Jessica Fye | Neutral | Maintains | $47.00 |
| Feb 20, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $60.00 |
| Feb 20, 2025 | RBC Capital | Luca Issi | Outperform | Reiterates | $70.00 |
| Feb 20, 2025 | Citigroup | David Lebowitz | Buy | Maintains | $64.00 |
| Feb 20, 2025 | BMO Capital | Kostas Biliouris | Market Perform | Maintains | $45.00 |
| Jan 15, 2025 | RBC Capital | Luca Issi | Outperform | Reiterates | $70.00 |
| Dec 20, 2024 | Needham | Joseph Stringer | Buy | Maintains | $60.00 |
| Nov 14, 2024 | Piper Sandler | Allison Bratzel | Overweight | Maintains | $62.00 |
| Nov 7, 2024 | Needham | Joseph Stringer | Buy | Reiterates | $60.00 |
| Nov 7, 2024 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $77.00 |
| Oct 9, 2024 | Guggenheim | Debjit Chattopadhyay | Buy | Maintains | $65.00 |
| Sep 26, 2024 | RBC Capital | Luca Issi | Outperform | Reiterates | $70.00 |
| Aug 26, 2024 | JP Morgan | Jessica Fye | Neutral | Maintains | $55.00 |
| Aug 2, 2024 | Guggenheim | Debjit Chattopadhyay | Buy | Maintains | $70.00 |
Ionis Pharmaceuticals Inc. (IONS) Competitors
The following stocks are similar to Ionis based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Ionis Pharmaceuticals Inc. (IONS) Financial Data
Ionis Pharmaceuticals Inc. has a market capitalization of $4.51B with a P/E ratio of -9.3x. The company generates $705.14M in trailing twelve-month revenue with a -64.4% profit margin.
Revenue growth is -30.2% quarter-over-quarter, while maintaining an operating margin of -48.9% and return on equity of -93.1%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Ionis Pharmaceuticals Inc. (IONS) Business Model
About Ionis Pharmaceuticals Inc.
Develops RNA-targeted therapeutics for genetic disorders.
Ionis Pharmaceuticals generates revenue by discovering and developing RNA-targeted therapeutics, primarily through its innovative antisense oligonucleotide technology. The company partners with leading pharmaceutical firms to enhance its drug pipeline and expand market reach, earning income from collaborations and potentially from product sales once approved.
Ionis has a strong pipeline of drugs addressing various diseases, including neurological, cardiovascular, metabolic, and cancer-related conditions. The company is at the forefront of personalized medicine, emphasizing the significance of genetic research in healthcare, which positions it as a key player in the biotechnology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
1,069
CEO
Dr. Brett P. Monia Ph.D.
Country
United States
IPO Year
1991
Website
www.ionis.comIonis Pharmaceuticals Inc. (IONS) Latest News & Analysis
Ionis Pharmaceuticals (IONS) saw a rise in share price with above-average trading volume, but recent earnings estimate revisions indicate potential weakness ahead.
Ionis Pharmaceuticals' share price spike on high volume suggests short-term interest, but negative earnings revisions indicate potential long-term weakness, impacting future investment decisions.
Ionis to host expert panel discussion on sHTG
16 days agoIonis Pharmaceuticals will host a webinar on April 14 at 11:00 a.m. ET discussing severe hypertriglyceridemia, featuring experts in lipidology and cardiology.
Ionis Pharmaceuticals is addressing unmet medical needs in severe hypertriglyceridemia, potentially signaling advancements in treatment, which could impact stock performance and market position.
Ionis Pharmaceuticals will participate in investor conferences on April 7, May 14, and May 21, 2025. Live webcasts will be available in the Investors & Media section of their website.
Ionis Pharmaceuticals' participation in key investor conferences signals potential updates on strategies or developments, influencing investor sentiment and stock performance.
Ionis has secured an undisclosed upfront payment from Sobi, along with potential milestone payments and a tiered royalty on future sales of the drug.
Ionis securing an upfront payment and potential future earnings from milestone payments and royalties indicates strong partnership value, positively impacting its financial outlook and stock performance.
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
24 days agoIonis Pharmaceuticals has licensed Sobi exclusive rights to commercialize olezarsen outside the U.S., Canada, and China for treating familial chylomicronemia syndrome, while retaining U.S. rights.
The licensing agreement expands Ionis Pharmaceuticals' market reach for olezarsen, potentially increasing revenue and strategic partnerships, enhancing its growth outlook.
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. Investors may want to monitor upcoming developments for potential stock movement.
Upcoming developments for Ionis Pharmaceuticals could influence stock performance, impacting investor sentiment and potential price movements. Earnings trends may signal future growth or risks.
Frequently Asked Questions About IONS Stock
What is Ionis Pharmaceuticals Inc.'s (IONS) stock forecast for 2025?
Based on our analysis of 32 Wall Street analysts, Ionis Pharmaceuticals Inc. (IONS) has a median price target of $59.50. The highest price target is $78.00 and the lowest is $37.00.
Is IONS stock a good investment in 2025?
According to current analyst ratings, IONS has 17 Buy ratings, 8 Hold ratings, and 1 Sell ratings. The stock is currently trading at $28.40. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IONS stock?
Wall Street analysts predict IONS stock could reach $59.50 in the next 12 months. This represents a 109.5% increase from the current price of $28.40. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Ionis Pharmaceuticals Inc.'s business model?
Ionis Pharmaceuticals generates revenue by discovering and developing RNA-targeted therapeutics, primarily through its innovative antisense oligonucleotide technology. The company partners with leading pharmaceutical firms to enhance its drug pipeline and expand market reach, earning income from collaborations and potentially from product sales once approved.
What is the highest forecasted price for IONS Ionis Pharmaceuticals Inc.?
Price targets from Wall Street analysts for IONS are not currently available. The stock is trading at $28.40.
What is the lowest forecasted price for IONS Ionis Pharmaceuticals Inc.?
The lowest price target for IONS is $37.00 from Salveen Richter at Goldman Sachs, which represents a 30.3% increase from the current price of $28.40.
What is the overall IONS consensus from analysts for Ionis Pharmaceuticals Inc.?
The overall analyst consensus for IONS is bullish. Out of 32 Wall Street analysts, 17 rate it as Buy, 8 as Hold, and 1 as Sell, with a median price target of $59.50.
How accurate are IONS stock price projections?
Stock price projections, including those for Ionis Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.